Covington & Burling advised Insmed Incorporated on the transaction. Insmed Incorporated (Nasdaq: INSM) (“Insmed”) announced its entrance into an agreement to amend its $350 million term...
You must be a Standard 1 Year member to access this content.
Covington advised Humacyte on the deal. Humacyte, Inc. announced its $150 million revenue-based funding arrangement, as well as a $10 million equity investment option, with Oberland...
You must be a Standard 1 Year member to access this content.
Covington advised Petrichor on the deal. Petrichor, a leading healthcare-dedicated growth capital provider, announced its $30 million financing of VERO Biotech Inc., a commercial-stage healthcare business dedicated...
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
Covington advised Marathon Asset Management LP on the deal. Marathon Asset Management LP announced a non-dilutive term loan for up to $100 million to Theratechnologies Inc. Marathon...
You must be a Standard 1 Year member to access this content.
